Media - Our stories

Explore our recent stories to see what drives us

30 July 2024

Grünenthal acquires US-based Valinor Pharma

Grünenthal acquires US-based Valinor Pharma
Grünenthal acquires the pharmaceutical company Valinor Pharma and becomes the global owner of Movantik® / Moventig® (naloxegol).

Movantik® is indicated for the oral treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The transaction further expands Grünenthal’s portfolio of established medicines and adds to the company’s growing U.S. business. Gross sales from Movantik® in the United States reached over $200 million in 2023.

Fact-Sheet Valinor Pharma & Movantik®

PR Grünenthal acquires US-company Valinor Pharma and becomes global owner of Movantik®

Further details on our company can be found in our annual report.

Responsible Usage Statement - Opioid-based medicines

Gabriel Baertschi, CEO, Grünenthal

“As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio.”

Gabriel Baertschi,

CEO, Grünenthal



Get in touch

We are keen to hear new ideas and discover assets that are relevant to our business. If you are interested in partnering with us, get in touch.
Contact us

Share this story: